| Zdroj: |
Hillmen, P, Cohen, D R, Cocks, K, Pettitt, A, Sayala, H A, Rawstron, A C, Kennedy, D B, Fegan, C, Milligan, D W, Radford, J, Mercieca, J, Dearden, C, Ezekwisili, R, Smith, A F, Brown, J, Booth, G A, Varghese, A M & Pocock, C 2011, ' A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia ', British Journal of Haematology, vol. 152, no. 5, pp. 570-578 . https://doi.org/10.1111/j.1365-2141.2010.08317.x |
| Popis: |
Combination fludarabine (F), cyclophosphamide (C) and rituximab (R) is the standard front-line therapy in chronic lymphocytic leukaemia (CLL), but appropriate treatment of relapsed/refractory CLL is less clear. Combined FC and mitoxantrone (M) has been reported to be effective in a single arm study, and rituximab when added to chemotherapy in CLL is synergistic. A randomized, two-stage, Phase II trial of FCM and FCM-R was conducted in relapsed CLL. The primary endpoint was response rate 2months after therapy, assessed according to the 2008 International Workshop CLL criteria. In addition, minimal residual disease (MRD) in the marrow was studied 2months after therapy, with MRD negativity defined as |
